Perigon Wealth Management LLC Acquires Shares of 53,000 DiaMedica Therapeutics, Inc. $DMAC

Key Points

• Perigon Wealth Management LLC acquired 53,000 shares of DiaMedica Therapeutics, valued at approximately $207,000, representing 0.12% of the company.
• Royal Bank of Canada made a remarkable 46,879.1% increase in its stake during the first quarter, owning 155,031 shares valued at $588,000 after purchasing an additional 154,701 shares.
• DiaMedica Therapeutics has a market cap of $354.59 million and recently experienced a slight stock decline of 0.1%.

Perigon Wealth Management LLC acquired a new stake in DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 53,000 shares of the company's stock, valued at approximately $207,000. Perigon Wealth Management LLC owned 0.12% of DiaMedica Therapeutics at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in DMAC. Royal Bank of Canada boosted its position in DiaMedica Therapeutics by 46,879.1% in the 1st quarter. Royal Bank of Canada now owns 155,031 shares of the company's stock valued at $588,000 after buying an additional 154,701 shares during the period. Jane Street Group LLC boosted its position in DiaMedica Therapeutics by 138.5% in the 1st quarter. Jane Street Group LLC now owns 100,669 shares of the company's stock valued at $382,000 after buying an additional 58,457 shares during the period. Goldman Sachs Group Inc. boosted its position in DiaMedica Therapeutics by 76.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 121,802 shares of the company's stock valued at $462,000 after buying an additional 52,854 shares during the period. Millennium Management LLC boosted its position in DiaMedica Therapeutics by 151.8% in the 4th quarter. Millennium Management LLC now owns 84,829 shares of the company's stock valued at $461,000 after buying an additional 51,139 shares during the period. Finally, Cornerstone Wealth Management LLC purchased a new stake in DiaMedica Therapeutics in the 1st quarter valued at about $62,000. 10.12% of the stock is owned by hedge funds and other institutional investors.

DiaMedica Therapeutics Stock Down 0.1%

NASDAQ DMAC opened at $6.86 on Thursday. The firm has a market cap of $354.59 million, a PE ratio of -9.94 and a beta of 1.40. The company has a 50 day moving average price of $5.91 and a 200 day moving average price of $4.66. DiaMedica Therapeutics, Inc. has a 52 week low of $3.19 and a 52 week high of $7.49.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.18) EPS for the quarter, hitting the consensus estimate of ($0.18). On average, equities research analysts anticipate that DiaMedica Therapeutics, Inc. will post -0.59 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DMAC has been the subject of several recent research reports. Wall Street Zen lowered shares of DiaMedica Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, September 26th. HC Wainwright restated a "buy" rating and issued a $12.00 price target on shares of DiaMedica Therapeutics in a report on Friday, August 15th. Lake Street Capital boosted their price target on shares of DiaMedica Therapeutics from $11.00 to $14.00 and gave the company a "buy" rating in a report on Friday, July 18th. Finally, Craig Hallum boosted their price target on shares of DiaMedica Therapeutics from $8.00 to $11.00 and gave the company a "buy" rating in a report on Friday, July 18th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, DiaMedica Therapeutics has an average rating of "Buy" and a consensus target price of $12.33.

Insider Activity at DiaMedica Therapeutics

In other news, major shareholder Jan Stahlberg acquired 1,542,857 shares of DiaMedica Therapeutics stock in a transaction that occurred on Wednesday, July 23rd. The stock was purchased at an average price of $3.50 per share, for a total transaction of $5,399,999.50. Following the purchase, the insider directly owned 6,764,465 shares in the company, valued at $23,675,627.50. The trade was a 29.55% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. In the last three months, insiders have purchased 2,542,857 shares of company stock worth $11,358,598. Insiders own 7.30% of the company's stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.

Want to see what other hedge funds are holding DMAC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.